Loading...
I am pleased to present our editors' picks for the Top Stories of 2012. As usual, we select those stories that have the greatest clinical impact or are particularly groundbreaking in their public health or preclinical findings.
Some of the stories have obvious direct relevance today, such as the studies on coformulated tenofovir/FTC/elvitegravir/cobicistat (“Quad”) and that drug's subsequent FDA approval and listing in HIV treatment guidelines. The FDA approval of tenofovir/FTC for HIV pre-exposure prophylaxis (PrEP) also has immediate implications for clinical practice, although many questions remain about implementing PrEP. By contrast, the data on dolutegravir are likely to become even more important next year, with the anticipated publication of studies already presented at major meetings and the likely FDA approval of this drug. Finally, the study on “waking up HIV” is an early salvo in what should be a growing body of literature on HIV cure strategies.
Without further ado, here are our top (published) stories of 2012:
Tenofovir/FTC Approved for PrEP . . .
Undetectable Viral Load — Not a Guarantee Against Transmitting HIV
HIV and the Clinical Manifestations of Accelerated Aging
Even at High CD4 Counts, Mortality Rates Are High in Untreated HIV Infection
The Latest “Vital Signs” for the U.S. HIV Epidemic Suggest an Emergency
No More Excuses: HIV Viral Load Monitoring Lowers Costs